Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces that it has received a letter of intent from its animal health partner. The purpose of this letter of intent is to guarantee both parties’ rights, confirming the discussions currently underway leading to the signing of the final agreement.
[button link=”http://www.quantum-genomics.com/www/wp-content/uploads/2015/12/QGC_PR_ADVANCE-HEALTH-ANIMAL_20151216_EN.pdf” target=”_blank” title=”Download Press Release” size=”small” color=”red”]
